Company news: Nature Publishing Group, Elsevier, Medicare

Share this article:
In addition to getting its own Facebook page September 10, Nature's Antibodypedia released its seventh version November 29. The publisher said in a statement that the new features include search-refining filters and Nature's manuscript annotation tool. The free, open-access resource includes a catalogue of more than 500,000 antibodies and the results of around 145,000 experiments. The Facebook page, which had almost 1,400 Likes at press time, includes Nature-posted queries such as, “How much research do you do when choosing antibodies to purchase? Any suggestions for providers to add?” and newsy posts like what the 2012 election could mean for science.

Elsevier has added four new medical board review apps. The latest titles are Braunwald's Heart Disease Review and Assessment, Emergency Medicine and Review, Rush University Medical Center Review of Surgery and Sleep Medicine Review: A problem-oriented approach. The titles include a teaser version to give users a sense of the content and can then be purchased from within the app. ITunes indicates the top in-app purchases have been for Surgery, Heart Disease and Emergency, which cost between $74.99 and $99.99. The latest mobile-optimized apps include bookmarks, interactive Q&A, among other features.

The idea of raising the age of Medicare eligibility as a way to save money is not as simple as it may appear, reported NPR. The problem: it would mean only patients with very costly medical care would be covered. Having healthier, 65-year-olds in the mix somewhat dilutes the financial impact, much like younger -- think 20-year-olds -- are great for insurers because they pay premiums but use fewer services, providing ballast for the more service-intense (i.e., older) patient population. Taking 65-year-olds out of the Medicare mix would be like pulling the healthy 20-somethings out of the pool, and could drive up Medicare premiums.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.